Hemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDA
Rhea-AI Summary
Hemogenyx Pharmaceuticals (OTC:HOPHF) filed its second annual IND report with the FDA for HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia, on April 14, 2026. The filing summarizes Year 2 clinical activity, manufacturing stability work, and planned dose escalation.
Key clinical details: a Phase 1 study enrolling up to 36 subjects (18 adults, 18 pediatric); three adult patients treated at the initial dose (7 × 10⁷ CAR+ cells); observed CAR-T expansion, reduced blast burden, no ICANS or dose-limiting toxicities, and mainly low-grade adverse events. Company plans further enrollment and dose escalation.
AI-generated analysis. Not financial advice.
Positive
- Phase 1 study ongoing with planned 36 evaluable subjects
- Three adult patients treated at initial dose of 7×10⁷ CAR+ cells
- CAR-T expansion and persistence observed in all treated subjects
- Reductions in blast burden noted in blood and/or bone marrow
- No ICANS or dose-limiting toxicities reported to date
Negative
- Only three patients treated — data remain preliminary and limited
- Results reported at a single, lowest dose level only
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML
LONDON, UK / ACCESS Newswire / April 14, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has submitted its Annual Report to the U.S. Food and Drug Administration (FDA) under the active Investigational New Drug (IND) application for HG-CT-1, the Company's proprietary CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML).
The annual report provides a comprehensive update on the Company's activities under the IND during the second year of the clinical trial of HG-CT-1 and includes the following key elements:
1. Individual Study Information:
The ongoing Phase 1 study is designed to evaluate the safety and preliminary efficacy of HG-CT-1 in adult and pediatric patients with R/R AML. The study plans to enroll up to 36 evaluable subjects (18 adults and 18 pediatric patients), with a primary objective of assessing safety based on dose-limiting toxicities.
As of the IND anniversary date, three adult patients have been enrolled and treated at the initial lowest dose level (7 × 10⁷ CAR+ cells).
Across these patients:
CAR-T cell expansion and persistence were observed in all subjects, with peak levels typically occurring between 14 and 28 days post-infusion
Reductions in blast burden were observed in peripheral blood and/or bone marrow
No immune effector cell-associated neurotoxicity syndrome (ICANS) or dose-limiting toxicities (DLTs) were reported
Adverse events were generally low grade and manageable
These findings remain preliminary due to the limited number of patients and evaluation at a single dose level.
2. Quality Summary Information:
The report includes data from investigations conducted during the reporting period relating to the stability of the HG-CT-1 drug product and its lentiviral vector manufacturing process, supporting continued clinical development.
3. Update to the General Investigational Plan:
The Company plans to continue patient enrollment and dose escalation in the upcoming year to further evaluate the safety profile and potential anti-leukemic activity of HG-CT-1.
This filing marks another important step in the Company's clinical development of HG-CT-1 and reaffirms its commitment to regulatory compliance and transparent communication.
Further updates will be provided as the trial progresses.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"Submitting our second annual IND report to the FDA represents continued progress in the development of HG-CT-1. While early-stage data remain preliminary, we are encouraged by the observed biological activity and manageable safety profile. We are focused on advancing the study through additional dose levels to further evaluate the therapeutic potential of HG-CT-1 for patients with relapsed or refractory AML."
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
AlbR Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire